The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 680 currently available and novel biosimilar products, detailing…
Heart failure (HF) is classified as acute or chronic, and both settings are the focus of this report. Although much progress has been made in the pharmacological management of HF, it mainly relates…
EPI Data Slicer
EPI Data Slicer
Biologics approved to treat immune indications (e.g., rheumatoid arthritis, Crohn’s disease) are among the most commercially successful biopharmaceutical products and offer a great opportunity to…
We expect the ulcerative colitis (UC) market to grow steadily over the next decade, primarily driven by the increasing use of non-tumor necrosis factor (TNF) biologics (e.g., Takeda’s Entyvio,…
EPI Data Slicer
EPI Data Slicer
EPI Data Slicer
EPI Data Slicer
EPI Data Slicer
EPI Data Slicer
EPI Data Slicer
EPI Data Slicer
EPI Data Slicer